Allstate (NYSE: ALL) has recently received a number of price target changes and ratings updates:
- 10/9/2025 – Allstate had its price target raised by analysts at JPMorgan Chase & Co. from $235.00 to $254.00. They now have an “overweight” rating on the stock.
- 10/8/2025 – Allstate had its price target raised by analysts at UBS Group AG from $235.00 to $250.00. They now have a “buy” rating on the stock.
- 10/8/2025 – Allstate had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 10/1/2025 – Allstate was given a new $233.00 price target on by analysts at Evercore ISI. They now have an “in-line” rating on the stock.
- 10/1/2025 – Allstate was downgraded by analysts at Evercore ISI from a “strong-buy” rating to a “hold” rating. They now have a $233.00 price target on the stock.
- 9/27/2025 – Allstate had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
- 9/26/2025 – Allstate was given a new $230.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
- 9/16/2025 – Allstate was upgraded by analysts at Wolfe Research to a “strong-buy” rating.
- 9/15/2025 – Allstate is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $235.00 price target on the stock.
- 8/20/2025 – Allstate had its price target raised by analysts at BMO Capital Markets from $230.00 to $235.00. They now have an “outperform” rating on the stock.
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.
Featured Articles
- Five stocks we like better than Allstate
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- The How And Why of Investing in Oil Stocks
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for The Allstate Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Allstate Corporation and related companies with MarketBeat.com's FREE daily email newsletter.